• About
    Copenhagen, Denmark, 6 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) invites to a presentation of the results from the clinical trial of FG001 used to guide surgery in patients with aggressive high-grade glioma brain cancer, which will first be presented at the 68th Scandinavian Neurosurgical Society (SNS) Congress held 14-16 May 2022, in Bergen, Norway

    As a follow-up on the presentation done by Principal Investigator and Chief Surgeon Jane Skjøth-Rasmussen in Bergen, FluoGuide hereby invites to an online presentation of the same data that will be presented at the SNS congress.

    Resume of the trial:
    In total, 40 patients have been administered FG001 that has been shown to be safe and well-tolerated. No serious drug related adverse events have been reported. Only a few drug-related adverse events were reported as grades 1 or 2, and no pattern or dose relation was observed

    The pharmacokinetic (PK) profile for FG001 was assessed for all dose levels. FG001 showed dose-dependent increases in exposure across dose levels in a linear manner.

    Tumor-to-background ratio (TBR) is a measure of the contrast. At the optimal dose and time, 36 mg administered the evening before the surgery, all patients revealed a clinically relevant TBR value.

    The histology samples from dose 36 mg, evening, and dose 48 mg, evening, have been unblinded and analyzed. The histology results confirm that FG001 lights up aggressive brain cancer.
  • Agenda
    • Welcome by Morten Albrechtsen, CEO
    • Presentation by Principal Investigator, Chief surgeon Jane Skjøth-Rasmussen, MD, PhD
    • Q&A
    • Future clinical trials in brain cancer by Morten Albrechtsen, CEO
    • Closing remarks by Morten Albrechtsen, CEO
  • Price
  • Language
  • Dial-in Number
    Please register for this Webinar to view the dial-in info.